PARIS--(BUSINESS WIRE)--Recent changes to the UK and Dutch pharmaceutical industries’ codes of best practices, and the proposal of a French-style “Sunshine Act” by the Health Ministry in June, herald a new regulatory framework in Europe for pharmaceutical and medical equipment companies. Because of these advances, companies will be hurrying to set up an internal mechanism for reporting and publishing all of their payments to health industry players to comply with these new prerequisites.
